When monoclonal antibody development intersects with computational science, a groundbreaking collaboration emerges: this is MATCH, or Monoclonal Antibody Development and Characterization Laboratory.
Leading this collaboration is our Valerio Chiarini, Ph.D., an expert in structural biology and bioinformatics, and Giuseppe Roscilli, our CTO, as part of the Rome Technopole project.
The effort to identify viable candidate mAbs for clinical trials encounters challenges, given the multitude of requisite human application criteria and the vast array of potential variants. Traditional experimental approaches prove both time and cost-intensive.
Modeling molecular interactions on high-performance computing (HPC) clusters offers the potential to address both issues and narrow down ideal candidates to validate experimentally.
Our in-silico methodology encompasses an integrated computational platform running on ENEA CRESCO6 HPC cluster, guiding the design and optimization of antibodies, selection of binding conformers, antigen docking, and profiling of binding forces.
Currently, our focus lies on the de-novo design of antibodies targeting specific epitopes, alongside the consolidation of artificial intelligence infrastructures to model novel antibodies from existing candidates.
For a deeper dive into our innovative process, explore our latest poster!
#pharma #pharmaceutical #biotech #biotechnology #antibodies #immunology #bioinformatics
